Keynote Speaker

RNA Binding Proteins in Virus Infection

Tumor and immune cell metabolism

Marina Kreutz studied Biology and perfomed her PhD thesis under the supervision of Prof. Reinhard Andreesen at the Albert-Ludwigs-Universität Freiburg (topic: Induction of human monocyte differentiation by Vitamin D3). She continued to work on this topic in Regensburg as a postdoc. In 1995, she moved to San Diego and worked as a research fellow at the University of California San Diego/UCSD (Prof. Dr. C. Glass). After her return to Germany, she graduated as “Privatdozent” (Habilitation) and finally became appointed as Professor for Molecular Oncology at the University Hospital Regensburg in 2012. Marina is also head of a Clinical Cooperation Group Immunometabolomics within the LIT-Leibniz Institute for Immunotherapy in Regensburg. Her main interest is the interplay between tumor-and immunometabolism. Currently the group focuses on different strategies to strengthen the response to immunotherapy in patients.

Cell biology (Tumor metastasis‬ - ‪Cell migration‬ - ‪Cell-matrix interaction‬)

Pharmaceutical Cell Biology (Mechanobiology - Optogenetics - Nanoparticles for Drug Delivery)

Hanna Engelke studied physics at Universität Bayreuth. After a PhD at LMU München in biophysics and a postdoc at UC Berkeley in mechanobiology, she worked as group leader at the department of chemistry of the LMU. From there, she moved to the University of Graz, where she currently holds a professorship for Pharmaceutical Cell Biology. Her lab focuses on mechanobiology, particularly the interactions between cells and the mechanics of the extracellular matrix. The lab develops tools to control matrix properties and intracellular signals in 3D cell culture models. With these tools, they investigate the influence of matrix and corresponding intracellular signaling on cell behavior. Another line of research in the lab is the development of nanoparticles for biomedical applications.

Keynote Talk (Oct. 8th, 1.30 pm): Cell-Matrix Interactions – from fibers to mechanotransduction

Cell behavior is strongly influenced by the chemical and mechanical properties of the surrounding matrix and vice versa, cells are constantly modifying their surrounding matrix. This interaction plays a key role in many biological processes ranging from development to diseases. To unravel this close interplay between cell behavior and matrix, we have developed techniques that allow us to control the matrix properties on the one hand and mechanotransduction in the cell on the other hand. Matrix properties that we control include stiffness, matrix fiber density, but also alignment of matrix fibers using microfluidics. In order to control mechanotransduction in the cell, we have developed a photo-activatable YAP, which allows us to activate YAP, a key mechanotransduction protein, with light and thus spatio-temporal control. I will show the application of these techniques to biological systems revealing the influence of underlying cell-matrix interactions and implications for in-vitro models of diseases.

Biosensors and Bioelectronics

János Vörös has studied Physics at the Eötvös Loránd University in Budapest. After receiving a diploma in Physics in 1995, he was a doctoral student at the Department of Biological Physics of the Eötvös University (in collaboration with Microvacuum Ltd.) where he received his PhD in Biophysics in 2000. Since 1998 he was a member of the BioInterface group in the Laboratory for Surface Science and Technology at the Department of Materials of ETH Zurich as visiting scientist, postdoc, and from 2004 as group leader of the Dynamic BioInterfaces group until 2006. 

Prof. Vörös is interested in research and teaching in the areas of Biosensors, Bioelectronics, and Bottom-up Neuroscience. His research group focuses on the development of novel biosensor techniques for diagnostics and drug discovery; and on interacting with well-defined neural networks.

Keynote Talk (Oct. 8th, 4.15 pm): Neuron microcircuits on HD-MEAs – an enabling technology towards biocomputing

Understanding how the human brain processes and stores information is undoubtedly one of the largest challenges of this century. Recent progress in human induced pluripotent stem cell (iPSC) technology in combination with emerging microphysiological systems provides an opportunity to address some of the challenges related to investigating the nervous system and its diseases. This talk will introduce new tools to create and to interact with well-defined neuronal networks in vitro. For example, asymmetric PDMS microchannels can be used to guide the axonal growth in the desired direction on top of microelectrode arrays‎ while nanochannels enable the tuning of the connectivity between pre- and postsynaptic neurons‎.‎ This allows studying fundamental neuroscience paradigms  with simple networks of real neurons, providing high-quality “big” data that could be used to infer precise computational models.‎ It also enables the creation of medically interesting sub-systems, such as the nociceptory pathway, mimicking their anatomical arrangement with human iPSC-derived cells towards drug testing and personalized medicine.‎ Finally, specific computationally interesting architextures can also be realized to achieve basic logic operations‎ and to serve as embedded parts in hybrid artificial-biological neural networks. 
All of the presented approaches are “scalable” which means that it is relatively straightforward to adapt the presented experimental methodologies for other systems.

 RNA Synthetic Biology

Chase Beisel is a Faculty Professor at the Botnar Institute of Immune Engineering. Prior to joining the BIIE, Chase was a tenured associate professor in the Department of Chemical & Biomolecular Engineering at North Carolina State University and a Full Professor and Head of Department at the Helmholtz Institute for RNA-based Infection Research, with a joint appointment in the Medical Faculty of the University of Würzburg. As part of the BIIE, Chase leads a research group devoted to bacterial immune engineering. His group aims to understand the functional diversity of immune systems bacteria employ to counter infections by bacteriophages and other mobile genetic elements and to translate discoveries into new innovations to improve the health and wellbeing of children and adolescents globally. His group’s work has driven seminal discoveries within CRISPR-Cas immune systems along with the development of diverse CRISPR-based technologies, which led to multiple awarded patents and two start-up companies (Locus Biosciences, Leopard Biosciences) Chase co-founded.

Keynote Talk (Oct. 9th, 9.15 am): CRISPR conflicts

CRISPR is best known as a revolutionary tool for genome editing, yet its origins lie in versatile adaptive immune systems in bacteria and archaea. While CRISPR can effectively memorize prior infections as genetically encoded guide RNAs that direct the immune system to the same sequence, bacteriophages have developed a collection of countermeasures to block CRISPR and proceed with the infection unabated. In this talk, I’ll describe my group’s work uncovering not only the diverse immune mechanisms employed by CRISPR but also how bacteriophages fight back, with an eye toward harnessing each new discovery to further expand and control the incredible suite of CRISPR technologies.

Smart drug delivery systems

Olivia Merkel has been a Professor of Drug Delivery at LMU Munich since 2015, Chair since 2022, and Co-Director of the Department of Pharmacy since 2024. She is a Registered Pharmacist, received a MS (2006) and a PhD (2009) in Pharmaceutical Technology as well as numerous awards, including an ERC Starting Grant, ERC Proof-of-Concept Grant and ERC Consolidator Grant, the APV Research Award and the Carl-Wilhelm-Scheele-Award. Merkel is the co-spokesperson for the BMBF Future Cluster CNAT-M and an author of over 120 articles and book chapters. She served as NIH reviewer from 2014-2015, SNSF reviewer from 2018-2022, is an Editorial Board member for JCR, EJPB, Molecular Pharmaceutics and other journals, Associate Editor for DDTR and WIREs Nanomedicine and Nanobiotechnology, was the President of the German Controlled Release Society in 2020 and the Chair of the CRS Focus Group on Transdermal and Mucosal Delivery from 2020-2022, and currently is a scientific advisory board member of Coriolis Pharma, AMW, and Corden Pharma as well as a co-founder of RNhale. Her research focuses mainly on RNA formulation and pulmonary delivery for the treatment of a variety of lung diseases.

Keynote Talk (Oct 9th, 1.00 pm): Polyspermines for therapeutic pulmonary RNA delivery

Delivery is the major hurdle thwarting the therapeutic potential of RNA medicines. While all siRNA drugs on the market target the liver, the lung offers a variety of currently undruggable targets which could be treated with RNA therapeutics. Hence, my lab rationally designs inhalable and biocompatible nanocarriers for efficient siRNA delivery to the lung. Poly(beta-amino ester)s (Fig. 1) are biodegradable cationic polymers capable of promoting nucleic acid delivery in vitro and in vivo and can be tailormade to investigate structure–function relationships. While biomaterials are commonly synthesized in large libraries and optimized empirically via one-variable-at-a-time experimentation, we combine Design-of-Experiments (DoE) with Molecular Dynamics Simulations and Machine Learning (ML) to accelerate the discovery and optimization process of polycationic siRNA nanocarriers at reduced wet-lab resources. Sophisticated in vitro and ex vivo models of the lung are available to screen therapeutic efficacy against respiratory viral infections, against transcription factors upregulated in asthma and COPD or against mutated oncogenes in the presence of relevant biologic barriers. Our previous results highlight oleylamine-modified spermine-based poly(β-amino ester)s (PBAEs) that efficiently encapsulate siRNA into nanoparticles <100 nm for up to 95% gene silencing in vitro. PBAE-based polyspermines successfully deliver siRNA for gene silencing in 2D cultures, Transwell® air-liquid-interface cultures, and in vivo. To compare polymer backbones, polyacrylamide (PAA)-based polyspermines were synthesized and resulted in more efficient siRNA delivery and gene silencing in Transwell® air-liquid-interface cultures compared with Lipofectamine but had a much more favorable safety profile in vitro and in vivo. After intratracheal administration to mice, the PAA-based polyplexes were efficiently taken up by Type II pneumocytes and successfully evaded recognition by macrophages in the lung. Additional in vivo experiments in models of disease are currently under way. Based on our preliminary data, polyspermines seem to be very promising candidates for RNA formulation and delivery with an excellent safety profile in the lung.